CREATE Medicines, Inc. (formerly Myeloid Therapeutics), a clinical-stage biotech pioneering in vivo multi-immune programming, today announced that clinical results from its Phase 1 MYE Symphony trial ...

CAMBRIDGE, MA / ACCESS Newswire / / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell ...

A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot ...

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

MRNA research enabled the remarkably fast production of COVID-19 vaccine candidates in the pandemic. But more broadly, the ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

South Africa's biggest pharmaceutical producer Aspen Pharmacare said on Friday it had reached a 25 million euro ($29.2 ...

This Nasdaq biotech in my Stocks and Shares ISA portfolio just got a shot in the arm. Here's why I'm almost past caring at this point. The post Up 14% yesterday, is it the end for this train wreck in ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

After months of uncertainty, Aspen has confirmed that its contractual dispute regarding the mRNA vaccine has been settled, ...

Messenger RNA (mRNA) therapeutics hold significant promise for the future of personalized cancer treatment, but persistent off-target effects and treatment-resistant tumor microenvironments have ...